Vor Biopharma Stock Total Debt
| VOR Stock | USD 0.79 0.01 1.25% |
Vor Biopharma fundamentals help investors to digest information that contributes to Vor Biopharma's financial success or failures. It also enables traders to predict the movement of Vor Stock. The fundamental analysis module provides a way to measure Vor Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vor Biopharma stock.
As of 11/22/2024, Total Debt To Capitalization is likely to grow to 0.20. Vor | Total Debt |
Vor Biopharma Company Total Debt Analysis
Vor Biopharma's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Vor Biopharma Total Debt | 35.66 M |
Most of Vor Biopharma's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vor Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Vor Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Vor Biopharma is extremely important. It helps to project a fair market value of Vor Stock properly, considering its historical fundamentals such as Total Debt. Since Vor Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vor Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vor Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Vor Total Debt Historical Pattern
Today, most investors in Vor Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vor Biopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Vor Biopharma total debt as a starting point in their analysis.
Vor Biopharma Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Vor Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Vor Biopharma has a Total Debt of 35.66 M. This is 98.7% lower than that of the Biotechnology sector and 89.02% lower than that of the Health Care industry. The total debt for all United States stocks is 99.33% higher than that of the company.
Vor Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vor Biopharma's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vor Biopharma could also be used in its relative valuation, which is a method of valuing Vor Biopharma by comparing valuation metrics of similar companies.Vor Biopharma is currently under evaluation in total debt category among its peers.
Vor Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Vor Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vor Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vor Biopharma's value.| Shares | Millennium Management Llc | 2024-06-30 | 389.6 K | Goldman Sachs Group Inc | 2024-06-30 | 375.3 K | Ensign Peak Advisors Inc | 2024-06-30 | 346.1 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 338.6 K | Susquehanna International Group, Llp | 2024-06-30 | 247.2 K | Jane Street Group Llc | 2024-06-30 | 222.5 K | Bridgeway Capital Management, Llc | 2024-06-30 | 165.9 K | Y-intercept (hong Kong) Ltd | 2024-06-30 | 132.3 K | Exchange Traded Concepts, Llc | 2024-06-30 | 117.8 K | Ra Capital Management, Llc | 2024-06-30 | 22.7 M | Fmr Inc | 2024-09-30 | 7.1 M |
Vor Fundamentals
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 24.72 M | ||||
| Shares Outstanding | 68.67 M | ||||
| Shares Owned By Insiders | 1.17 % | ||||
| Shares Owned By Institutions | 81.20 % | ||||
| Number Of Shares Shorted | 1.37 M | ||||
| Price To Book | 0.75 X | ||||
| EBITDA | (114.37 M) | ||||
| Net Income | (117.86 M) | ||||
| Cash And Equivalents | 151.09 M | ||||
| Cash Per Share | 3.97 X | ||||
| Total Debt | 35.66 M | ||||
| Debt To Equity | 0.24 % | ||||
| Current Ratio | 12.95 X | ||||
| Book Value Per Share | 2.22 X | ||||
| Cash Flow From Operations | (100.29 M) | ||||
| Short Ratio | 2.99 X | ||||
| Earnings Per Share | (1.64) X | ||||
| Target Price | 11.92 | ||||
| Number Of Employees | 168 | ||||
| Beta | -0.41 | ||||
| Market Capitalization | 54.67 M | ||||
| Total Asset | 198.13 M | ||||
| Retained Earnings | (340.08 M) | ||||
| Working Capital | 125.23 M | ||||
| Net Asset | 198.13 M |
About Vor Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vor Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vor Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vor Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Vor Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vor Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vor Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Vor Stock
The ability to find closely correlated positions to Vor Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vor Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vor Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vor Biopharma to buy it.
The correlation of Vor Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vor Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vor Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vor Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.